Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Dose Escalation of HBI-2438 in Patients With Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation

NCT05485974 is registered in ClinicalTrials.gov with HUYABIO International, LLC. as lead sponsor.

NCT NCT05485974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05485974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Dose Escalation of HBI-2438 in Patients With Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation
Lead sponsor
HUYABIO International, LLC.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 1, 2022
Completion date
December 31, 2026
Enrollment
44 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer of pancreas, colon cancer, colorectal cancer, lung cancer, non small cell lung cancer, solid tumor